SCHEMBL5446141

SCHEMBL5446141

C=Cc1cnc(Nc2ccc(S(=O)(=O)N3CCCN(C(=O)O)CC3)cc2F)nc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TGM2 P21980 5/20 0.47
TGM1 P22735 5/20 0.47
F13A1 P00488 4/20 0.47
NAMPT P43490 1/20 0.42
TSHR P16473 1/20 0.40
LMNA P02545 1/20 0.40
MAPT P10636 3/20 0.39
CYP3A4 P08684 2/20 0.39
POLB P06746 1/20 0.39
KDM4E B2RXH2 1/20 0.39
GAA P10253 1/20 0.39
KMT2A Q03164 3/20 0.39
MEN1 O00255 2/20 0.38
USP2 O75604 1/20 0.38
TP53 P04637 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
HSD17B10 Q99714 1/20 0.38
DPP4 P27487 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5437791 0.89 ALDH1A1 (0.43) TGM2TGM1F13A1TSHRLMNA
SCHEMBL14501663 0.88 MAPT (0.48) TGM2TGM1F13A1NAMPTTSHR
SCHEMBL14490218 0.87 TGM2 (0.54) TGM2TGM1F13A1CYP3A4CYP2C9
SCHEMBL5442020 0.85 TGM2 (0.48) TGM2TGM1F13A1NAMPT
SCHEMBL5452245 0.83 F13A1 (0.47) TGM2TGM1F13A1PKM
SCHEMBL5453894 0.80 TGM2 (0.47) TGM2TGM1F13A1
SCHEMBL5435040 0.79 TGM2 (0.48) TGM2TGM1F13A1POLBKDM4E
SCHEMBL14490222 0.78 TGM2 (0.54) TGM2TGM1F13A1TSHRLMNA
SCHEMBL5440818 0.76 F13A1 (0.47) TGM2TGM1F13A1TSHRLMNA
SCHEMBL14501664 0.76 MEN1 (0.47) TSHRLMNAMAPTPOLBKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070149508-A1 Six membered heteroaromatic inhibitors targeting resistant kinase mutations TARGEGEN, INC. (US) 2007-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149508-A1 Six membered heteroaromatic inhibitors targeting resistant kinase mutations ABL1, KDR, BCR TGM2 1975/4885TGM1 904/4885F13A1 4382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.